# A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

> **NCT06497556** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 338 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer
- KRAS G12C Lung Cancer

## Interventions

- **DRUG:** Divarasib
- **DRUG:** Sotorasib
- **DRUG:** Adagrasib

## Key facts

- **NCT ID:** NCT06497556
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-09-23
- **Primary completion:** 2027-09-30
- **Final completion:** 2029-11-30
- **Target enrollment:** 338 (ACTUAL)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06497556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06497556, "A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06497556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*